Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AE58054 in Moderate Alzheimer's Disease
NCT01019421Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Dec 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Lu AE58054 + Donepezil with Placebo + Donepezil (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 24 weeks. Started Dec 2009; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01019421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019421.